Lipokinetic studies with gemfibrozil (CI-719).
Gemfibrozil (CI-719) has proved to be an effective agent in reducing the plasma triglyceride levels in experimental animals and in patients with endogenous hypertriglyceridaemia. We have confirmed these findings.
D001059:Apoproteins / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007700:Kinetics; D050356:Lipid Metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000494:pharmacology*; D014992:Xylenes / Q000494:pharmacology*
D001059:Apoproteins; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes